PPHM and Tarvacin discussion - Page 2 - iHUB Organization

Preciouslife1 · 12-01-2005, 00:27

I think Tamiflu is going to wind up being useless unless an adjuvant of some sort can be administered to enhance it's efficacy...in comes in Tarvacin.

Yes, I am adding to PPHM, I bought a chunk last week...now is a good time to buy PPHM, because if they land a substantial contract with NIAID to move forward with testing Tarvacin in-vivo it will take some money. I personally, think Preston Marx is the catalyst behind all of this scientific interest,....DUKE is working on HIV...CL...you and I both know what this about....but to have Dr. Monto step on board for influenza...geez. Here is a mab that has Five indications in the works. Cancer, HIV, CMV, HCV and Influenza...it's a big ticket item. The cancer and HCV studies IMO have really begun infusing in July-Sept and onward...there has been NO HALT. Which means they (PPHM) can state "it appears it's safe"...

PPHM is the best deal out there right now, and Dr. Monto is not serving on half or any of the AVIAN pumpette stocks.

A mab that works on five potential indications? Big ticket item.....who will the suitor be....my guess is GSK, Roche or BMY.

katie...

12-01-2005, 18:49

Hello, everyone,

I am new here. I am a big PPHM fan, or gambler, too.

I now have one question for Preciouslife1:

If Tarvacin, or its potential whatever, is promising, why has PPHM being dumped so heavily in 2005 and still under $1 till today?

Thanks!

Andreea · 12-01-2005, 22:53

Hello

In response to Katie's post posted here by PreciousLife1, all I can say that it has always been an issue of how "clean" organizations are. I mean organizations such as PPHM they all have noble goals, but can they actually keep their actions focused and "clean". The project that they are working on right now, looks a bit too much to be handled by only one organization. Do not get me wrong, it's great that they are gathering the best experts there are in the world in the medical field in order to achieve their goal, just personally think that they should focus on one thing at a time. Also, one might ask the question who is really behind this organization, will the funding go towards the intended research.

By the way just out of curiosity, does anyone know who is (are) the sponsors, the funding providers for conducting this research?
I would also be interested in knowing with which other organizations if any is PPHM working hand in hand in collaboration?
Are there any successful products out there, found and researched by PPHM?
Again I think it great that they are gathering all the great minds in the medical field in order to tackle this research! The best of luck to them!!!

Thanks!

P.S. You think it would be possible to get in touch with one of the scientists involved on this research?

Preciouslife1 · 12-02-2005, 00:09

First off hello. Why is PPHM trading for around $1?
PPHM had a poor history of bringing great technology to fruition like their Cotara drug and VTA which they still have a broad range of patents on. However, their is different leadership, their is a platform with Tarvacin that is so broad and encompassing that it could boggle the mind as to how many applications it could be used for as a stand alone drug or as an adjuvant.
The NIAID which is a Gov't agency is behind some of the trials going on. They are very well aware of what Tarvacin is capable of doing and the ongoing trials in Antiviral and anticancer will be producing human data for the first time.
The reason that the PPS is so low is that Wall Street is a show me, don't tell me entity that rewards companies for proven data.
The long history of Techniclone which is now PPHM has been
great platforms, great science, but not enough capital to see them through all the trials. They Cotara through into Phase3 and same in China with stunning results when the biotech market got slammed a few years ago and they had to do death spiral financing with offshore financiers and PIPE's.
Since Dr. Thorpe has brought Tarvacin into the limelight, the trial centers have been coming TO PPHM to get Tarvacin into their centers for various trials in cancer, viral, HepC etc.
To get into MD Anderson, Duke Medical, Tulane Medical, Godofsky Center, Stanford, means that they have seen something they really like with this platform. The Gov't also has seen data and they have given a grant to UTSW to Dr. Thorpe for studies. The capital shortage and the expanding share float are the only things holding this back from rising PPS for the time being. Once human data starts flowing, there will be a plethora of collaberations and licensing deals which will bring capital infusion without the stiff financial penalties they have been paying. They are very well known by Genentech, Glaxo, Chiron, Roche etc. The whole key is how good the human data is. The data on guinea pigs was unprecedented because Tarvacin is highly effective on most enveloped viruses and there is not relapse due to Tarvacins unique properties. Go to Tarvacin.com and read up on what and how Tarvacin works. This "could" be a very rare opportunity for an investor to become extremely wealthy with a well timed investment. Nothing like Tarvacin has been seen before and that is why all these world reknowned MD's and scientists are lining up on PPHM's SRB. They have seen some data and want in. I am Not pumping this by any means. I own several other biotechs and don't even mention them here as I haven't seen anything like what Tarvacin could be able to do on such a wide basis of ailments. I appreciate any and all comments, thoughts and ideas on this. I have been in PPHM since '99 and have accumulated a very large stake. I have a friend who is in The HepC trial at the Godofsky Center in Bradenton, Fl. and while he is under confidentiality agreement, is looking real well and doesn't appear to have any adverse effects from Tarvacin dosing. This is getting long so ask questions and hopefully I can answer some and do your DD on this. With the H5N1 avian flu possibly getting ready to mutate and spread during peak flu season, it would be wise to look into this company as the US Gov't already has, Take care all and appreciate the replies....Presh1

Preciouslife1 · 12-02-2005, 01:19

http://www.prnewswire.com/cgi-bin/st...2005,+07:01+AM

Once human data starts coming out, it will turn into a blizzard of information available on the web, especially under Tarvacin search on Google.Goodnight all..

rootemail · 12-02-2005, 10:24

Thanks a lot for your long answer. I may need little more time to digest it.
I found this forum by googling "Tarvacin". I am going to try to get some more people here, and ask more questions as well.

Quote:

Originally Posted by Preciouslife1

http://www.prnewswire.com/cgi-bin/st...2005,+07:01+AM

Once human data starts coming out, it will turn into a blizzard of information available on the web, especially under Tarvacin search on Google.Goodnight all..

12-02-2005, 16:13

I was sent here by someone to check out your info.

I run SSHGuru.com and we have a PPHM board as well.

Also live chat.

Your board has some impressive people.

Scott

12-02-2005, 17:43

I added 40k PPHM today at .97 to get to 150k.

I added after reading this board.

You are all welcome to a free month at SSHGuru.com. No credit card or anything necessary.

Scott

Preciouslife1 · 12-02-2005, 20:02

I wish ALL the best with your new shares. This has the potential to be a big winner once the human data comes out.
Thanks for the offer, that was nice of you.
These additions to the SRB are because they have seen preliminary data and they want in too.

I posted this on PPHM Raging Bull board yesterday:

Add Dr. Monto to these four renowned scientists and you have a lineup that is most impressive for any companies SRB.
Along with Dr. Thorpe and Soares, some of the most brilliant minds in their fields now reside within PPHM domain.......

As members of the Peregrine SRB, Drs. Barry and Prince will be joining Drs. Preston Marx and Stephen Smith, who provide expertise in the treatment of HIV and other viral indications and Drs. Philip Thorpe and Melina Soares who developed the Tarvacin Anti-Viral platform.

Peter Barry, Ph.D.

Dr. Barry has extensive experience in many aspects of virology, cell biology, immunology and molecular biology with a main emphasis on the elucidation of the mechanisms of rhesus CMV persistence and pathogenesis as a non-human primate model of human CMV. Development of the macaque model is important because human CMV is strictly species-specific and macaques share strong immunologic, physiologic, developmental and evolutionary relationships with humans. Dr. Barry's research goals have addressed two broad areas. The first focuses on the mechanisms enabling the virus to establish lifelong persistence in an immunocompetent host despite the development of vigorous antiviral immune responses. In particular, his research focuses on those viral proteins that modulate host immune response. The second research focus is directed towards a better understanding of the mechanisms of CMV pathogenesis in rhesus monkeys during fetal infection and simian AIDS, two highly relevant models of human CMV disease in humans. Knowledge from these two research interests is being applied by Dr. Barry's laboratory towards the development of novel anti-CMV vaccines and chemotherapeutic strategies to limit CMV infection and disease potential.

Alfred Prince, M.D.

Dr. Prince is a world-renowned virologist with expert focus on hepatitis. Currently, Dr. Prince is head of the Laboratory of Virology for The New York Blood Center, research professor of pathology at New York University School of Medicine, founding chairman of the Hepatitis Research Foundation and founding chairman of the International Consortium for Blood Safety. Dr. Prince was first to demonstrate the role of hepatitis B virus (HBV) in chronic liver disease; introduced the world's first blood screening for HBV at the New York Blood Center; was first to report the existence of the virus now termed HCV that causes post-transfusion hepatitis distinct from HBV; developed the first low-cost HBV vaccine; developed the first procedure for sterilization of blood to eliminate the risk of HBV, HCV and HIV transmission by blood products; developed an immunotherapy for chronic HBV infection in a chimpanzee model; founded the International Task Force for Hepatitis B Immunization which accelerated universal immunization against HBV worldwide; founded the International Consortium for Blood Safety and developed a multivalent vaccine candidate for HBV, HCV and HIV.

Dr. Preston A. Marx is a career virologist with over 25 years of experience in academic and research settings. He has published more than 190 research articles, 170 of which are on AIDS and HIV (Human immunodeficiency virus). He is professor of Tropical Medicine at Tulane University Health Sciences Center in New Orleans and the editor-in-chief of the Journal of Medical Primatology. His research is focused on AIDS, human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) and simian models of AIDS. He gives lectures on the origin of HIV in Africa and HIV vaccines to scientists, health professionals and general audiences. On occasion, he provides consultation and advice on virology, AIDS vaccine development and anti-viral drug development.

Preciouslife1 · 12-02-2005, 20:05

Dr. Arnold Monto to Help Evaluate and Advance Tarvacin(TM) Anti-Viral as a
Potential Treatment for Common and H5N1 Avian Influenza Strains -

- Tarvacin Already in Human Trials for Hepatitis C and Cancer -

TUSTIN, Calif., Nov. 30 /PRNewswire-FirstCall/ -- Peregrine
Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company with a
portfolio of innovative, clinical stage product candidates for viral diseases
and cancer, today announced that it has appointed noted influenza expert
Arnold S. Monto, M.D., professor of epidemiology at the School of Public
Health of the University of Michigan, to its Scientific Resource Board.
Dr. Monto's expertise in influenza will support further evaluation of
Peregrine's clinical stage drug, Tarvacin(TM) Anti-Viral, for the treatment of
influenza, including the H5N1 avian influenza strain. Tarvacin Anti-Viral is
in a Phase I clinical trial for the treatment of chronic hepatitis C infection
and is being studied preclinically for use in the treatment of cytomegalovirus
and HIV, as well as influenza infections.
"Dr. Monto is one of the leading influenza experts in the world, and his
expertise should be especially valuable to Peregrine as we accelerate our
efforts to assess Tarvacin as a potentially important new influenza therapy,"
said Steven King, president and CEO of Peregrine. "As we have previously
reported, Tarvacin Anti-Viral binds to members of six different virus
families, including common influenza strains, and we are expanding our
existing collaborations with federal, private and academic research centers to
evaluate Tarvacin in animal models as both a stand-alone agent and in
combination with existing influenza therapies."
Tarvacin is a monoclonal antibody with unique anti-viral properties. It
attaches to specific cellular components called phospholipids found on the
surface of virus particles, including influenza and certain other virus
strains, as well as on the outer surface of human host cells only when they
are infected with these viruses. Tarvacin helps stimulate the body's natural
immune defenses to destroy both the virus particles and the infected cells.
Since the targeted phospholipids are not exposed on healthy cells, they are
not affected by Tarvacin, which in studies to date appears to be safe and well
tolerated. In addition, because Tarvacin's target is derived from the
infected human cell, its efficacy is less likely to be affected by mutations
in the virus, an issue that has led to drug resistance with other anti-viral
medications.
In preclinical studies Tarvacin has shown encouraging activity both as a
stand-alone agent and in combination with existing drugs. In addition, it has
the potential for broad activity against most types of influenza virus
strains, regardless of the specific genetic make-up of the virus itself.
"Tarvacin Anti-Viral has a unique and intriguing mechanism of action
supported by interesting science, and I look forward to helping to fully
evaluate its potential as a possible new therapy for influenza," said
Dr. Monto. "I am on record as stating that a flu pandemic is inevitable at
some point, so it is essential that we be prepared with a full arsenal of
preventative and therapeutic measures. Tarvacin may prove to be a promising
new therapeutic option in the anti-viral arena, and I look forward to
contributing to its progress."
Dr. Monto's influenza research is supported by grants from the National
Institutes of Health and the Centers for Disease Control. In January of this
year he authored an article on the threat of an avian flu pandemic in the New
England Journal of Medicine. Dr. Monto currently consults with a number of
federal agencies on influenza prevention, treatment and preparedness.
Among his many honors and special appointments, Dr. Monto is currently
finishing a term as president of the American Epidemiological Society, and he
has served as director of the University of Michigan's Bioterrorism
Preparedness Initiative, as chairman of its Department of Population Planning
and International Health, as a scholar-in-residence at the National Academy of
Sciences and Institute of Medicine, in the Division of Communicable Diseases
at the World Health Organization, and as a staff member in the Virus Disease
Section of the National Institute of Allergy and Infectious Diseases. Dr.
Monto has authored numerous scientific publications on influenza and other
public health issues. He received his undergraduate and M.D. degrees from
Cornell and completed a post-doctoral fellowship in infectious diseases at
Stanford.
In addition to its anti-viral properties, Tarvacin also binds to
phospholipids exposed on tumor blood vessels in all solid cancers tested to
date. Tarvacin Anti-Cancer is currently in a multi-center Phase I clinical
trial for patients with advanced refractory solid tumors.

About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a
portfolio of innovative product candidates in clinical trials for the
treatment of cancer and viral diseases. The company is pursuing three
separate clinical trials in cancer and anti-viral indications with its lead
product candidates Tarvacin(TM) and Cotara(R). Peregrine also has in-house
manufacturing capabilities through its wholly owned subsidiary Avid
Bioservices, Inc. (http://www.avidbio.com), which provides development and
biomanufacturing services for both Peregrine and outside customers.
Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement:
Statements in this press release which are not purely historical,
including statements regarding Peregrine Pharmaceutical's intentions, hopes,
beliefs, expectations, representations, projections, plans or predictions of
the future are forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. The forward-looking statements
involve risks and uncertainties including, but not limited to, the risk that
results of pre-clinical studies showing Tarvacin Anti-Viral's potential broad
applicability against most types of influenza virus strains and its potential
effectiveness in combination therapy will not be consistent in human testing.
It is important to note that the company's actual results could differ
materially from those in any such forward-looking statements. Factors that
could cause actual results to differ materially include, but are not limited
to, the timing to enroll patients in this clinical study or any study the
Company is conducting and the uncertainty of clinical trial results in this
study or any clinical study. Our business could be affected by all of the
foregoing and a number of other factors, including the risk factors listed
from time to time in the Company's SEC reports including, but not limited to,
the annual report on Form 10-K for the year ended April 30, 2005. The Company
cautions investors not to place undue reliance on the forward looking
statements contained in this press release. Peregrine Pharmaceuticals, Inc.
disclaims any obligation, and does not undertake, to update or revise any
forward-looking statements in this press release.

Investors Media
Brod & Schaffer Barbara Lindheim
(800) 987-8256 GendeLLindheim BioCom Partners
ir@peregrineinc.com (212) 918-4650

12-03-2005, 01:33

I posted this on SSHGuru.com, but I thought I'd share here also...

Press Release Source: Peregrine Pharmaceuticals, Inc.

Peregrine Pharmaceuticals to Host Second Quarter FY2006 Conference Call
Friday December 2, 1:43 pm ET

TUSTIN, Calif., Dec. 2 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM - News), will host a conference call and simultaneous webcast on Friday, December 9, 2005. Peregrine's management will discuss financial results for the second quarter ended October 31, 2005, and will provide an update on the company's progress. The second quarter results will also be reported in a press release distributed on the morning of December 9th before the market opens.
ADVERTISEMENT

The conference call and live webcast will begin at 11:00 a.m. ET/ 8:00 a.m. PT. Please call the following number approximately 10 minutes prior to the scheduled time of the call: 1-800-860-2442. A telephonic replay of the conference call will also be available through December 16, 2005, by calling 1-877-344-7529, passcode 382933#.

To listen to a live broadcast of the call over the Internet, please visit: http://www.peregrineinc.com . The broadcast will be archived on Peregrine's website for 30 days.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and viral diseases. The company is pursuing three separate clinical trials in cancer and anti-viral indications with its lead product candidates Tarvacin(TM) and Cotara®. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers.

Investors: Brod & Schaffer, LLC
Betsy Brod/Jonathan Schaffer
ir@peregrineinc.com
(800)987-8256

strad · 12-03-2005, 11:57

I maintain a thread on 'Agonist' with a LOT of info on tarvacin. It is primarily focussed on tarvacin's potential as H5N1 avian flu therapy, but the thread contains all the info one would need to get a clear understanding into the drug's design, history, mechanism of action, and of course-it's incredibly broad potential as a therapeutic for several different disease states.

The particular thread, being focussed more towards flu, contains the most extensive collection of papers into how influenza infections progress, how the body fights, and how tarvacin fits, even- in the case of H5N1- in terms of quieting cytokine "storm" (what really kills in nasty flus) via greatly increased phagocytosis of infected (apoptotic) cells. (data from Thorpe patents & patnt applications).

But the thread is also full of info regarding safety studies, other details from Thorpe's patents, etc...

It's a long read- the kind of thing that would take a few hours to get through, or a weekend.

You're all welcome to stop by-

http://discuss.agonist.org/smf/index.php?topic=22737.0

strad

Preciouslife1 · 12-03-2005, 12:28

Any and all info about PPHMa and Tarvacin is welcome!
Thanks for posting your link and I will share it with RB PPHM too.
Tarvacin's broad platform has so much potential to be medicine changing in many areas. Now just waiting on human data to come in. Pr's and CC's due up next. New appointments at PPHM and job shifting cause one to believe things are really hopping behind the scenes....Take care PL1

12-03-2005, 20:29

Thanks Strad, I'll be posting a link on SSHGuru.com so my members can read that also.

Scott

rootemail · 12-05-2005, 13:23

Some more questions:

1) When is Tarvacin's Phase 1 trial scheduled to complete?

2) If the Phase 1 trial with human data succeeds, will PPHM be over $10 like VPHM?

3) If the Phase 1 trial with human data fails, what will we have to face? Is it possible for PPHM going to bankruptcy?

Thanks!